Talmadge E. King
Impact in
- Pulmonary and Respiratory Medicine top 0.01%
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Medical Imaging and Pathology Studies
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Pulmonary Hypertension Research and Treatments
- Occupational and environmental lung diseases
- Inhalation and Respiratory Drug Delivery
- Physiology top 0.1%
- Sarcoidosis and Beryllium Toxicity Research
Papers in
-
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis 172
- Medical Imaging and Pathology Studies 39
- Pulmonary Hypertension Research and Treatments 22
- Chronic Obstructive Pulmonary Disease (COPD) Research 18
- Inhalation and Respiratory Drug Delivery 14
- Physiology 52
- Sarcoidosis and Beryllium Toxicity Research 37
- Co-authors
- Moisés Selman (5 shared papers)Annie Pardo (5 shared papers)Harold R. Collard (38 shared papers)Paul W. Noble (36 shared papers)Williamson Z. Bradford (34 shared papers)Marvin I. Schwarz (26 shared papers)Brett Ley (13 shared papers)Steven A. Sahn (19 shared papers)
- Journals
- American Journal of Respiratory and Critical Care Medicine (38 papers)CHEST Journal (31 papers)European Respiratory Journal (12 papers)Respiratory Medicine (8 papers)Thorax (7 papers)
- Partner nations
- United StatesUnited KingdomItaly
In The Last Decade
Talmadge E. King
235 papers receiving 30.1k citations
Talmadge E. King's Hit Papers
Peers
Comparison fields: 5 of 166
- Pulmonary and Respiratory Medicine 24.7k
- Physiology 6.1k
- Rheumatology 1.9k
- Pathology and Forensic Medicine 1.8k
- Epidemiology 2.7k
Countries citing papers authored by Talmadge E. King
This map shows the geographic impact of Talmadge E. King's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Talmadge E. King with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Talmadge E. King more than expected).
Fields of papers citing papers by Talmadge E. King
This network shows the impact of papers produced by Talmadge E. King. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Talmadge E. King. The network helps show where Talmadge E. King may publish in the future.
Co-authors
The 25 scholars most cited alongside Talmadge E. King, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 237 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis Hit paper breakdown → | 2014 | 2657 |
| 2 | Idiopathic pulmonary fibrosis Hit paper breakdown → | 2011 | 1655 |
| 3 | Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials Hit paper breakdown → | 2011 | 1501 |
| 4 | Idiopathic Pulmonary Fibrosis: Prevailing and Evolving Hypotheses about Its Pathogenesis and Implications for Therapy Hit paper breakdown → | 2001 | 1420 |
| 5 | Clinical Course and Prediction of Survival in Idiopathic Pulmonary Fibrosis Hit paper breakdown → | 2010 | 1272 |
| 6 | A Multidimensional Index and Staging System for Idiopathic Pulmonary Fibrosis Hit paper breakdown → | 2012 | 875 |
| 7 | Predicting Survival in Idiopathic Pulmonary Fibrosis Hit paper breakdown → | 2001 | 658 |
| 8 | Changes in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis Hit paper breakdown → | 2003 | 561 |
| 9 | Idiopathic Pulmonary Fibrosis Hit paper breakdown → | 2001 | 483 |
| 10 | A Placebo-Controlled Trial of Interferon Gamma-1b in Patients with Idiopathic Pulmonary Fibrosis Hit paper breakdown → | 2004 | 465 |
| 11 | The Clinical Course of Patients with Idiopathic Pulmonary Fibrosis Hit paper breakdown → | 2005 | 445 |
| 12 | BUILD-3: A Randomized, Controlled Trial of Bosentan in Idiopathic Pulmonary Fibrosis Hit paper breakdown → | 2011 | 443 |
| 13 | 2004 | 430 | |
| 14 | 2009 | 412 | |
| 15 | 2005 | 402 | |
| 16 | 1989 | 382 | |
| 17 | 2001 | 373 | |
| 18 | Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial Hit paper breakdown → | 2009 | 371 |
| 19 | 2007 | 367 | |
| 20 | Forced Vital Capacity in Patients with Idiopathic Pulmonary Fibrosis: Test Properties and Minimal Clinically Important Difference Hit paper breakdown → | 2011 | 364 |
About Talmadge E. King
Talmadge E. King is a scholar working on Pulmonary and Respiratory Medicine, Physiology, Epidemiology, Pathology and Forensic Medicine and Rheumatology, having authored 237 papers that have together received 31.0k indexed citations. Recurring topics across this work include Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (172 papers), Medical Imaging and Pathology Studies (39 papers), Sarcoidosis and Beryllium Toxicity Research (37 papers), Pulmonary Hypertension Research and Treatments (22 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (18 papers), Systemic Sclerosis and Related Diseases (17 papers), Eosinophilic Disorders and Syndromes (15 papers) and Inhalation and Respiratory Drug Delivery (14 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (24.7k citations), Physiology (6.1k citations), Rheumatology (1.9k citations), Pathology and Forensic Medicine (1.8k citations) and Epidemiology (2.7k citations). Talmadge E. King has collaborated with scholars based in United States, United Kingdom and Italy. Frequent co-authors include Moisés Selman, Annie Pardo, Harold R. Collard, Paul W. Noble, Williamson Z. Bradford, Marvin I. Schwarz, Brett Ley, Steven A. Sahn, Lisa Lancaster and Roland M. du Bois. Their work appears in journals such as American Journal of Respiratory and Critical Care Medicine, CHEST Journal, European Respiratory Journal, Respiratory Medicine and Thorax.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.